Trial Profile
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Abraxis BioScience; Celgene Corporation
- 06 Nov 2008 Status changed from active, no longer recruiting to discontinued, based on information from ClinicalTrials.gov.
- 10 Mar 2008 The expected completion date for this trial is now 1 Dec 2008.
- 10 Mar 2008 Status changed from recruiting to in progress.